title: Changes in CSF neurotransmitters in infantile spasms.
abstract: Cerebrospinal fluid (CSF) from 7 patients with infantile spasms (mean age: 6.7 months) was collected before and after treatment with adrenocorticotropic hormone (ACTH). The concentration of neurotransmitter metabolites was analyzed using high-performance liquid chromatography and compared to the metabolite concentration in the CSF from 7 age-matched controls (mean age: 6.1 months). Pretreatment levels of CSF 5-hydroxyindoleacetic acid (5-HIAA), homovanillic acid, 3-methoxy-4-hydroxyphenyl glycol (MHPG), and kynurenine were significantly lower in infantile spasm patients compared to controls. Following treatment, marked increases in 5-HIAA and decreases in kynurenine levels were observed in the CSF of the 5 infants whose seizures were eliminated or reduced by ACTH. In the 2 nonresponders 5-HIAA levels decreased. The level of MHPG was reduced slightly in 5 infants, including the 2 nonresponders, and was increased in 2 responders. CSF homovanillic acid levels increased in 4 infantile spasm infants and decreased in 3 following ACTH. These data demonstrate that the presence of seizures in infantile spasms is associated with a significant decrease in serotonergic activity and that elimination of seizures by ACTH is accompanied by increased serotonin turnover. The simultaneous increase of 5-HIAA and decrease of kynurenine, an alternate metabolite of tryptophan, suggests an underlying disturbance of tryptophan metabolism in infantile spasms. The possibility that elimination of seizures by ACTH may be related to decreased production of certain kynurenine metabolites, particularly quinolinic acid, is discussed.
authors.affiliation: Department of Psychology, San Diego State University, CA 92182.
authors.forename: P J
authors.initials: PJ
authors.lastname: Langlais
authors.forename: M L
authors.initials: ML
authors.lastname: Wardlow
authors.forename: H
authors.initials: H
authors.lastname: Yamamoto
mesh_terms: D000324:Adrenocorticotropic Hormone / Q000627:therapeutic use; D005260:Female; D006719:Homovanillic Acid / Q000134:cerebrospinal fluid; D006801:Humans; D006897:Hydroxyindoleacetic Acid / Q000134:cerebrospinal fluid; D007223:Infant; D007737:Kynurenine / Q000134:cerebrospinal fluid; D008297:Male; D008734:Methoxyhydroxyphenylglycol / Q000134:cerebrospinal fluid; D018377:Neurotransmitter Agents / Q000134:cerebrospinal fluid*; D012701:Serotonin / Q000502:physiology; D013036:Spasms, Infantile / Q000134:cerebrospinal fluid* / Q000188:drug therapy; D014364:Tryptophan / Q000378:metabolism
chemical_list: D018377:Neurotransmitter Agents; D012701:Serotonin; D007737:Kynurenine; D008734:Methoxyhydroxyphenylglycol; D006897:Hydroxyindoleacetic Acid; D014364:Tryptophan; D000324:Adrenocorticotropic Hormone; D006719:Homovanillic Acid